Tyra Biosciences, Inc. (TYRA)
| Market Cap | 966.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -75.45M |
| Shares Out | 52.47M |
| EPS (ttm) | -1.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,321 |
| Open | 18.21 |
| Previous Close | 18.26 |
| Day's Range | 17.85 - 18.41 |
| 52-Week Range | 10.38 - 20.67 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 26.33 (+43.02%) |
| Earnings Date | May 9, 2024 |
About TYRA
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and othe... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TYRA stock is "Strong Buy." The 12-month stock price forecast is $26.33, which is an increase of 43.02% from the latest price.
News
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
- TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 million at Q1 2024 - - Susa...
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S.
CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large...
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
- Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 - - TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 - - Initiated SURF201 Phase 1 study and dosed ...
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Feb. 27, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target lar...
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
CARLSBAD, Calif. , Feb. 2, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
CARLSBAD, Calif. , Feb. 1, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
- Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300- - Received FDA feedback on TYRA-300 Phas...
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
CARLSBAD, Calif. , Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
- Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patient to be dosed in TYRA-2...
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target la...
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference
CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target la...
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
-Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study on track; first patient to...
Tyra Biosciences Announces FDA Orphan Drug Designation for TYRA-300 for the Treatment of Achondroplasia
CARLSBAD, Calif. , Aug. 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 25, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target larg...
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
-SURF301 Phase 1/2 oncology study continues to advance- - Expanded TYRA-300 clinical development into achondroplasia- -IND for TYRA-200 cleared with Phase 1 study on track for 2H 2023- -Strong cash po...
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
-Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia- -Cleared IND for TYRA-200 Ph...
Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia
- In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024- -Conference call a...
Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300
-TYRA-300 is the first oral, FGFR3-selective agent to be evaluated in the clinic- -Conference call and webcast today, Nov. 29th, at 9:00 am ET- CARLSBAD, Calif. , Nov. 29, 2022 /PRNewswire/ -- Tyra Bi...
Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights
-Pipeline on track; SURF301 study to be initiated; IND for TYRA-200 to be filed by year-end 2022- -Well-capitalized with cash and cash equivalents of $263.2 million as of Q3 2022- CARLSBAD, Calif. , N...
Tyra Biosciences Announces Planned Chief Financial Officer Transition
-Esther van den Boom to transition to an advisor at year-end 2022- -Alan Fuhrman to be named Chief Financial Officer- CARLSBAD, Calif. , Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TY...
Tyra Biosciences to Present Preclinical Data on TYRA-200, an FGFR1/2/3 Inhibitor, at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
CARLSBAD, Calif. , Oct. 13, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and impr...
Tyra Biosciences to Participate at September 2022 Investor Conferences
CARLSBAD, Calif. , Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and impr...
Tyra Biosciences to Present Preclinical Data on TYRA-300, an FGFR3-selective Inhibitor, at ESMO 2022 Congress
CARLSBAD, Calif. , Sept. 5, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and impr...
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
-IND clearance received from FDA to proceed with SURF301 Study of TYRA-300- -Pipeline on track; IND for TYRA-200 to be filed in 2H 2022- -Well-capitalized with cash and cash equivalents of $275.1 mill...